PDCD1 and neoplasm: Tumor-infiltrating Tregs express numerous negative costimulatory molecules (such as PD-L1 and PD-L2) that inhibit CD8+ T-cell activation and interact with the receptor PD-1 on CD8+ T cells to block TCR signaling, thereby repressing the activity of CD8+ T cells (48).